CD47 and non-Hodgkin lymphoma: For the first time, the increased expression of CD47 in malignancies was reported in ovarian carcinoma [26,27], and was later confirmed in various malignant diseases: acute myeloid leukemia (AML), non-Hodgkin’s lymphoma (NHL), breast cancer, melanoma, leiomyosarcoma, osteosarcoma, and is associated with their worsening forecast [28,29,30,31,32,33].